Praxis Precision Medicines Inc (PRAX) Stock Price, Quote & News

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molec...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 300 8460

Website: praxismedicines.com

Address:

99 High Street, 30th Floor, Boston, United States

JodieChristy Aug. 7 at 9:46 PM

Biotech Valuation Overload? My Top 4 High-Conviction Value Picks To Outsmart The Market! $INSM is trading strong around $131.10 right now! $PTGX is trading strong around $146.00 right now! $BBIO is trading strong around $84.48 right now! $PRAX is trading strong around $360.76 right now! While the broader biotech sector looks insanely overvalued, I filter strictly for late-stage clinical or early commercial winners featuring elite management, massive broad pipelines, $10B+ peak sales potential, and prices at or below intrinsic value. My current high-conviction watchlist features exactly four names: $INSM,$PTGX, $BBIO, and$PRAX.[Live Trading Strategy]: Avoid chasing overpriced hype scale into key support levels methodically and let value do the heavy lifting!

2 · Reply

Trainguy1 Aug. 7 at 5:15 PM

$PRAX Clinical & Pipeline Milestones — Q4 2026: Topline data expected from the EMERALD trial for relutrigine in broad DEEs. Late 2026 / 2027: Amended study designs and progress updates for the vormatrigine epilepsy program following initial trial re-evaluations. 2027: Expected topline results for the elsunersen EMBRAVE3 registrational trial in early-seizure-onset SCN2A DEE.

0 · Reply

Trainguy1 Aug. 7 at 5:05 PM

$PRAX Upcoming PDUFA Dates - December 27, 2026: Relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). January 29, 2027: Ulixacaltamide for the treatment of essential tremor (ET) in adults.

0 · Reply

NoHandOutz Aug. 7 at 1:24 PM

$IOVA $SITM $PRAX ZENA drone manufacturer is getting a big squeeze this morning!!

1 · Reply

topstockalerts Aug. 6 at 11:53 PM

$PRAX price keeps grinding higher in a very orderly way

0 · Reply

justiceforb_85 Aug. 6 at 10:35 PM

$PRAX ulixacaltamide will be a blockbuster.

0 · Reply

AngusMacbeth Aug. 6 at 7:03 PM

$PRAX Lifesci Capital reiterated a BUY rating and bumped PT from $719 to $754.

0 · Reply

AngusMacbeth Aug. 6 at 6:56 PM

$PRAX Needham reiterated a BUY rating and nudged price target up from $575 to $582.

0 · Reply

StocktwitsNews Aug. 6 at 5:49 PM

These Two Stocks Hit Fresh 52-Week Highs Today – DCTH Clocks Best Day In Nearly 15 Months $DCTH $PRAX https://stocktwits.com/news/equity/markets/dcth-prax-stocks-hit-52-week-high-heres-why/cZoBddERJJk

0 · Reply

StocktwitsNews Aug. 6 at 5:42 PM

PRAX Q2 2026 Earnings Summary $PRAX https://stocktwits.com/news/earnings/earnings/prax-q2-2026-earnings-summary/cZoB5ziRJJS

0 · Reply

Praxis Precision price target raised to $462 from $449 at RBC Capital

2026-08-07T12:01:15.000Z - 7 days ago

Praxis Precision price target raised to $514 from $400 at Baird

2026-08-07T11:00:47.000Z - 7 days ago

Praxis Precision price target raised to $362 from $323 at Wells Fargo

Aug 6, 2026, 8:30 AM EDT - 8 days ago

Praxis Precision Medicines Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 8 days ago

Praxis Precision Medicines Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 8 days ago

Praxis Precision Medicines Quarterly report: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 8 days ago

Praxis Precision Medicines Slides: Corporate presentation

Aug 4, 2026, 4:01 PM EDT - 9 days ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 30, 2026, 4:01 PM EDT - 14 days ago

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

2026-07-13T09:25:04.000Z - 4 weeks ago

Praxis Precision initiated with a Buy at Goldman Sachs

2026-07-07T12:10:42.000Z - 5 weeks ago

Praxis Precision, Remagine Labs announce research collaboration and license pact

Jul 7, 2026, 8:00 AM EDT - 5 weeks ago

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Jun 29, 2026, 4:30 PM EDT - 6 weeks ago

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies

2026-06-29T12:10:54.000Z - 6 weeks ago

Praxis Precision price target raised to $575 from $510 at Needham

2026-06-22T12:19:56.000Z - 7 weeks ago

Praxis Precision granted breakthrough therapy designation for elsunersen

Jun 22, 2026, 8:00 AM EDT - 7 weeks ago

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants

2026-06-17T20:37:28.000Z - 2 months ago

Praxis Precision initiated with an Outperform at RBC Capital

Jun 10, 2026, 9:00 AM EDT - 2 months ago

Praxis Precision Medicines Transcript: AGM 2026

Jun 8, 2026, 8:00 AM EDT - 2 months ago

Praxis Precision Medicines Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 4:01 PM EDT - 2 months ago

Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference

2026-06-02T16:19:35.000Z - 2 months ago

Praxis Precision falls -15.4%

2026-06-02T13:37:44.000Z - 2 months ago

Praxis Precision price target lowered to $616 from $715 at Truist

2026-06-02T12:23:18.000Z - 2 months ago

Praxis Precision price target lowered to $650 from $750 at Oppenheimer

2026-06-02T12:07:49.000Z - 2 months ago

Praxis Precision price target lowered to $162 from $166 at Wedbush

2026-06-02T11:42:18.000Z - 2 months ago

Praxis Precision price target lowered to $810 from $843 at BTIG

2026-06-02T11:24:46.000Z - 2 months ago

Praxis Precision price target lowered to $400 from $433 at Baird

2026-06-02T10:27:13.000Z - 2 months ago

Praxis Precision price target lowered to $1,201 from $1,245 at H.C. Wainwright

2026-06-02T08:30:10.000Z - 2 months ago

Praxis Precision price target lowered to $374 from $420 at Deutsche Bank

Jun 1, 2026, 6:11 PM EDT - 2 months ago

Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study

2026-06-01T21:09:16.000Z - 2 months ago

Praxis Precision Medicines trading resumes

Jun 1, 2026, 4:15 PM EDT - 2 months ago

Praxis Precision Medicines Provides Vormatrigine Program Update

May 12, 2026, 7:20 PM EDT - 3 months ago

Praxis Precision Medicines Transcript: Bank of America Global Healthcare Conference 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Praxis Precision Medicines Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Praxis Precision Medicines Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Praxis Precision Medicines Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 7, 2026, 7:00 AM EDT - 3 months ago

Praxis Precision Medicines Slides: Corporate presentation

May 4, 2026, 4:01 PM EDT - 3 months ago

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Praxis Precision Medicines Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Praxis Precision Medicines Proxy statement: Proxy filing

Apr 14, 2026, 7:30 AM EDT - 4 months ago

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Mar 30, 2026, 4:01 PM EDT - 4 months ago

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

Mar 2, 2026, 11:50 AM EST - 5 months ago

Praxis Precision Medicines Transcript: TD Cowen 46th Annual Health Care Conference

Feb 19, 2026, 8:00 AM EST - 6 months ago

Praxis Precision Medicines Earnings Call Transcript: Q4 2025

Feb 19, 2026, 8:00 AM EST - 6 months ago

Praxis Precision Medicines Earnings release: Q4 2025

Feb 19, 2026, 8:00 AM EST - 6 months ago

Praxis Precision Medicines Annual report: Q4 2025

Feb 19, 2026, 7:30 AM EST - 6 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 19, 2026, 7:00 AM EST - 6 months ago

Praxis Precision Medicines Slides: Corporate presentation

Feb 11, 2026, 1:00 PM EST - 6 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 9, 2026, 4:01 PM EST - 6 months ago

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

Feb 2, 2026, 9:57 AM EST - 6 months ago

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

Jan 22, 2026, 10:26 AM EST - 7 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 12, 2026, 7:00 AM EST - 7 months ago

Praxis Precision Medicines Slides: Corporate presentation

Jan 8, 2026, 4:45 PM EST - 7 months ago

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

Jan 6, 2026, 11:15 PM EST - 7 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Jan 6, 2026, 4:03 PM EST - 7 months ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Dec 29, 2025, 8:00 AM EST - 8 months ago

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Dec 11, 2025, 8:00 AM EST - 8 months ago

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Dec 9, 2025, 4:01 PM EST - 8 months ago

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Dec 4, 2025, 4:10 PM EST - 9 months ago

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Dec 4, 2025, 4:01 PM EST - 9 months ago

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Nov 24, 2025, 1:00 PM EST - 9 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Nov 20, 2025, 4:01 PM EST - 9 months ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Nov 18, 2025, 8:30 AM EST - 9 months ago

Praxis Precision Medicines Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 9:30 AM EST - 9 months ago

Praxis Precision Medicines Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 7:00 AM EST - 9 months ago

Praxis Precision Medicines Slides: Corporate Presentation

Nov 7, 2025, 12:30 PM EST - 9 months ago

Praxis Precision Medicines Transcript: Fireside Chat

Nov 5, 2025, 8:00 AM EST - 10 months ago

Praxis Precision Medicines Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 10 months ago

Praxis Precision Medicines Quarterly report: Q3 2025

Nov 3, 2025, 9:58 AM EST - 10 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Oct 16, 2025, 11:45 PM EDT - 10 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Oct 16, 2025, 2:14 PM EDT - 10 months ago

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Oct 16, 2025, 12:02 PM EDT - 10 months ago

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Oct 16, 2025, 8:00 AM EDT - 10 months ago

Praxis Precision Medicines Transcript: Study Result

Oct 16, 2025, 8:00 AM EDT - 10 months ago

Praxis Precision Medicines Press release: Study Result

Oct 16, 2025, 8:00 AM EDT - 10 months ago

Praxis Precision Medicines Slides: Study Result

Oct 16, 2025, 7:09 AM EDT - 10 months ago

Praxis Precision Medicines' movement disorder drug shows promise in trials

Sep 29, 2025, 7:00 AM EDT - 11 months ago

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

Sep 10, 2025, 8:30 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:01 PM EDT - 1 year ago

Praxis Precision Medicines to Participate in September Investor Conferences

Sep 2, 2025, 10:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Post-IEC Discussion with Praxis Precision Medicines (PRAX) Webinar

Aug 25, 2025, 4:01 PM EDT - 1 year ago

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

Aug 7, 2025, 11:00 AM EDT - 1 year ago

Praxis Precision Medicines Transcript: Fireside Chat

Aug 5, 2025, 5:50 PM EDT - 1 year ago

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 5, 2025, 10:00 AM EDT - 1 year ago